Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Cancer Control

Volumn 16, Issue 2, 2009, Pages 108-121

  Mauro, Michael J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; BLEEDING; BONE MARROW SUPPRESSION; BULLOUS DERMATITIS; CANCER RELAPSE; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DYSPNEA; EDEMA; ELECTROLYTE DISTURBANCE; ENZYME INHIBITION; FATIGUE; FLUID RETENTION; GENE MUTATION; HEADACHE; HEART LEFT VENTRICLE FAILURE; HEMATOLOGICAL PARAMETERS; HUMAN; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NAUSEA; PATIENT MONITORING; PLEURA EFFUSION; PREDICTION; PROGNOSIS; PRURITUS; QT PROLONGATION; RASH; REVIEW; RISK REDUCTION; SIDE EFFECT; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

EID: 65249086246     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480901600203     Document Type: Review

References (118)

1. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006;145(12):913-923.
2. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia V2.2009. http://www.nccn.org/ professionals/physician-gls/PDF/cml.pdf. Accessed February 9, 2009.
3. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809-1820. Epub 2006 May 18.
4. Giralt SA, Arora M, Goldman JM, et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol. 2007;137(5):461-467. Epub 2007 Apr 24.
5. Bittencourt H, Funke V, Fogliatto L, et al. Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase. Bone Marrow Transplant. 2008;42(9):597-600. Epub 2008 Aug 4.
6. Steegman JL, Michallet M, Morra E, et al. Imatinib use in chronic phase CML in clinical practice: the UNIC study. J Clin Oncol. 2008;26(May 20 suppl):7077. Abstract.
7. Lucas CM, Wang L, Austin GM, et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia. 2008;22(10):1963-1966. Epub 2008 Aug 28.
8. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008; 26(20):3358-3563. Epub 2008 Jun 2.
9. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399-401.
10. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500-4505.
11. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7(2):129-141.
12. Blake SJ, Lyons AB, Hughes TP. Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro. J Cell Mol Med. 2008 Sep 15. [Epub ahead of print.]
13. Bristol-Myers Squibb Company. Sprycel® (dasatinib) prescribing information. http://packageinserts.bms.com/pi/pi-sprycel.pdf. Accessed February 9, 2009.
14. Novartis Pharmaceuticals Corporation. Gleevec® (imatinib) prescribing information. http://www.pharma.us.novartis.com/product/pi/pdf/gleevec-tabs.pdf. Accessed February 9, 2009.
15. Novartis Pharmaceuticals Corporation. Tasigna® (nilotinib) prescribing information. Available at http://www.pharma.us.novartis.com/product/ pi/pdf/tasigna.pdf. Accessed February 9, 2009.
16. Mauro MJ, Deininger MW. Chronic myeloid leukemia in 2006: a perspective. Haematologica. 2006;91(2):152-158.
17. Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev. 2006;20 (1):29-41. Epub 2005 Mar 2.
18. Kantarjian HM, Cortes J, Guilhot F, et al. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns. Cancer. 2007;109(7):1365-1375.
19. Hughes T. ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring. Hematology Am Soc Hematol Educ Program. 2006; 211-218.
20. Weisser M, Schmid C, Schoch C, et al. Resistance to pretransplant imatinib therapy may adversely affect the outcome of allogeneic stem cell transplantation in CML. Bone Marrow Transplant. 2005;36(11):1017-1018.
21. Jabbour E, Cortes J, Kantarjian HM, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006; 108(4):1421-1423. Epub 2006 Apr 6.
22. Lee SJ, Kukreja M, Wang T, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008;112(8):3500-3507. Epub 2008 Jul 29.
23. Hehlmann R, Hochhaus A, Baccarani M, et al. Chronic myeloid leukaemia. Lancet. 2007;370(9584):342-350.
24. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006;108(5):1478-1484. Epub 2006 Apr 20.
25. Kantarjian HM, O'Brien S, Cortes JE, et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003;97(4):1033-1041.
26. Schoch C, Schnittger S, Bursch S, et al. Comparison of chromosome banding analysis, interphase-and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 2002;16(1):53-59.
27. Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112(8):3330-3338. Epub 2008 Aug 6.
28. Kantarjian H, O'Brien S, Shan J, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008;112(4):837-845.
29. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or sub-optimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112(12):4437-4444. Epub 2008 Aug 20.
30. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23): 2408-2417.
31. Druker BJ, Guilhot F, O'Brien S, et al. Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study. J Clin Oncol (2006 ASCO Annu Meet Proc Part I). 2006;24(18S June 20 suppl): 6506. Abstract.
32. Kumar L. Chronic myelogenous leukaemia (CML): an update. Natl Med J India. 2006;19(5):255-263.
33. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63(4):789-799.
34. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukaemia treated with interfer-on alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90(11):850-858.
35. Hasford J, Pfirrmann M, Hehlmann R, et al. Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy. Semin Hematol. 2003;40(1):4-12.
36. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349(15):1423-1432.
37. Forrest DL, Trainor S, Brinkman RR, et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leukemia Res. 2009;33(2):271-275. Epub 2008 Aug 31.
38. Kantarjian H, Smith TL, McCredie KB, et al. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood. 1985;66(6):1326-1335.
39. Swolin B, Weinfeld A, Westin J, et al. Karyotypic evolution in Ph-pos-itive chronic myeloid leukemia in relation to management and disease progression. Cancer Genet Cytogenet. 1985;18(1):65-79.
40. Sokal JE, Gomez GA, Baccarani M, et al. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood. 1988;72(1):294-298.
41. O'Dwyer ME, Mauro MJ, Kurilik G, et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood. 2002;100(5):1628-1633.
42. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003;101(10):3794-3800. Epub 2003 Jan 30.
43. Huntly BJ, Guilhot F, Reid AG, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood. 2003;102(6):2205-2212. Epub 2003 May 15.
44. Quintas-Cardama A, Kantarjian H, Talpaz M, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood. 2005;105(6):2281-2286. Epub 2004 Nov 30.
45. Calabrese G, Fantasia D, Di Gianfilippo R, et al. Fluorescence in situ hybridization analysis of minimal residual disease and the relevance of the der(9) deletion in imatinib-treated patients with chronic myeloid leukemia. Haematologica. 2006;91(7):994-995.
46. Kim DH, Popradi G, Sriharsha L, et al. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia. Cancer. 2008;113(4):772-781.
47. Bianchini M, Gargallo P, Alu F, et al. Determination of BCR-ABL over-expression by correlating qRT-PCR and IP-FISH in imatinib treated CML patients. Blood (ASH Annu Meet Abstracts). 2007;110:1958. Abstract.
48. Larson RA, Druker BJ, Guilhot F, et al. Correlation of pharmacoki-netic data with cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib: an analysis of IRIS study data. Blood (ASH Annu Meet Abstracts). 2006;108:429. Abstract.
49. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109(8):3496-3499. Epub 2006 Dec 27.
50. White D, Saunders V, Lyons AB, et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood. 2005;106(7):2520-2526. Epub 2005 Jun 14.
51. White D, Saunders V, Grigg A, et al. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol. 2007;25(28):4445- 4451.
52. White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107); reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006;108(2):697-704. Epub 2006 Apr 4.
53. Dressman MA, Malinowski R, McLean LA, et al. Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571). Clin Cancer Res. 2004;10(7): 2265-2271.
54. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006;103(8):2794-2799. Epub 2006 Feb 13.
55. Frank O, Brors B, Fabarius A, et al. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia. 2006;20(8)1400-1407. Epub 2006 May 25.
56. Yong AS, Szydlo RM, Goldman JM, et al. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood. 2006;107(1):205-212. Epub 2005 Sep 6.
57. Zheng C, Li L, Haak M, et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia. 2006;20(6):1028-1034.
58. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 2003;112(6):831-843.
59. Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol. 2003;11(1):35-43.
60. Deininger M. Resistance to imatinib: mechanisms and management. J Natl Compr Canc Netw. 2005;3(6):757-768.
61. Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer. 2005;103(8):1659-1669.
62. Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004;18: 1321-1331.
63. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105(7): 2640-2653. Epub 2004 Dec 23.
64. Nicolini FE, Corm S, Le QH, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia. 2006;20:1061-1066.
65. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102(1):276-283. Epub 2003 Mar 6.
66. Hochhaus A, Erben P, Branford S, et al. Hematologic and cytoge-netic response dynamics to nilotinib (AMN107) depend on the type of BCR-ABL mutations in patients with chronic myelogenous leukemia (CML) after imatinib failure. Blood (ASH Annu Meet Abstracts). 2006;108:749. Abstract.
67. von Bubnoff N, Manley PW, Mestan J, et al. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood. 2006;108(4):1328-1333. Epub 2006 Apr 13.
68. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006;66(1):473-481.
69. Goldman J. Monitoring minimal residual disease in BCR-ABL-posi-tive chronic myeloid leukemia in the imatinib era. Curr Opin Hematol. 2005; 12(1):33-39.
70. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol. 2005;23(18):4100-4109. Epub 2005 May 2.
71. Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-nai've patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. 2005; 106(6):2128-2137. Epub 2005 May 24.
72. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37. Epub 2006 Mar 7.
73. Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 2003;17(12):2401-2409.
74. Quintas-Cardama A, Kantarjian HM, Jones D, et al. Delayed achievement of molecular responses is associated with increased risk of progression among patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) treated with imatinib (IM). Blood (ASH Annu Meet Abstracts). 2006;108:432. Abstract.
75. Martinelli G, Iacobucci I, Rosti G, et al. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. Ann Oncol. 2006;17(3):495-502. Epub 2006 Jan 10.
76. Barnes DJ, Palaiologou D, Panousopoulou E, et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesy-late in chronic myeloid leukemia. Cancer Res. 2005;65(19):8912-8919.
77. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesy-late therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103(8):2873-2878. Epub 2003 Dec 24.
78. Marin D, Goldman JM, Olavarria E, et al. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood. 2003;102(7):2702- 2703; author reply 2703-2704.
79. O'Brien S, Tefferi A, Valent P. Chronic myelogenous leukemia and myeloproliferative disease. Hematology Am Soc Hematol Educ Program. 2004:146-162.
80. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of ima-tinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003;101(2):473-475. Epub 2002 Sep 12.
81. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109(12):5143-5150. Epub 2007 Feb 22.
82. Kantarjian H, Larson R, Guilhot F, et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 2009;115(3):551-560.
83. Zonder JA, Pemberton P, Brandt H, et al. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res. 2003;9(6):2092-2097.
84. Jabbour E, Kantarjian H, Atallah E, et al. Impact of imatinib mesylate dose escalation on resistance and sub-optimal responses to standard-dose therapy in patients (pts) with chronic myeloid leukemia (CML). Blood (ASH Annu Meet Abstracts). 2007;110:1035. Abstract.
85. Rousselot PH, Facon T, Paquette R, et al. Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CML-CP) resistant to standard-dose imatinib: 2-year follow-up data from START-R. J Clin Oncol. 2008;26:(May 20 suppl):7012. Abstract.
86. Deininger MW, O'Brien SG, Ford JM, et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21(8):1637-1647. Epub 2003 Mar 13.
87. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resis-tant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531-2541.
88. Quintas-Cardama A, Kantarjian H, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myeloge-nous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood. 2007;109(2):497-499. Epub 2006 Sep 21.
89. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109(6):2303-2309. Epub 2006 Nov 30. Erratum in: Blood. 2007;110(5):1438.
90. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;109 (10):4143-4150. Epub 2007 Jan 30.
91. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109(8): 3207-3213. Epub 2006 Dec 21.
92. Mauro MJ, Baccarani M, Cervantes F, et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol. 2008;26 (May 20 suppl):7009. Abstract.
93. Porkka K, Martinelli G, Ottmann O, et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant Philadelphia-chromosome-positive acute lymphoblastic leukemia: 24-month data from START-L. Presented at the 13th Annual Congress of the European Hematology Association, June 13-15, 2008, Copenhagen, Denmark. 2008:1. Abstract.
94. Rea D, Dombret H, Kim DW, et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in accelerated phase 24-month data from START-A. Presented at the 13th Annual Congress of the European Hematology Association, June 13-15, 2008, Copenhagen, Denmark. 2008:982. Abstract.
95. Saglio G, Dombret H, Rea D, et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in blast phase: 24-month data from the START program. Presented at the 13th Annual Congress of the European Hematology Association, June 13-15, 2008, Copenhagen, Denmark. 2008:880. Abstract.
96. Hochhaus A, Branford S, Radich J, et al. Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations. J Clin Oncol (2007 ASCO Annu Meet Proc, Part I). 2007;25(18S June 20 suppl):7023. Abstract.
97. Quintas-Cardama A, Kantarjian HM, Munden R, et al. Pleural effusion in patients (pts) with chronic myelogenous leukemia (CML) treated with dasatinib after imatinib failure. Blood (ASH Annu Meet Abstracts). 2006; 108:2006. Abstract 2164.
98. Shah NP, Kantarjian HM, Kim D-W, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and-intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26(19):3204-3212. Epub 2008 Jun 9.
99. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354 (24):2542-2551.
100. Rosti G, le Coutre P, Bhalla K, et al. A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myel-ogenous leukemia (CML) in chronic phase (CP). J Clin Oncol (2007 ASCO Annu Meet Proc, Part I). 2007;25(18S June 20 suppl):7007. Abstract.
101. le Coutre P, Gattermann N, Hochhaus A, et al. A phase II study of nilo-tinib administered to imatinib resistant or intolerant patients with chronic myel-ogenous leukemia (CML) in accelerated phase (AP). J Clin Oncol (2007 ASCO Annu Meet Proc, Part I). 2007;25(18S June 20 suppl):7026. Abstract.
102. Giles FJ, le Coutre P, Bhalla K, et al. A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myel-ogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib. J Clin Oncol (2007 ASCO Annu Meet Proc Part I). 2007;25(18S June 20 suppl):7038. Abstract.
103. Larson R, Ottman O, Kantarjian H, et al. A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myel-ogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). J Clin Oncol (2007 ASCO Annu Meet Proc, Part I). 2007;25(18S June 20 suppl):7040. Abstract.
104. Kantarjian H, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540-3546. Epub 2007 Aug 22.
105. Kantarjian H, Hochhaus A, Cortes J, et al. Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance. Blood (ASH Annu Meet Abstracts). 2007;110:735. Abstract.
106. le Coutre P, Giles FJ, Apperley J, et al. Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or-intolerance: update of a phase II study. J Clin Oncol. 2008;26(May 20 suppl):7050. Abstract.
107. Ottmann O, Larson R, Kantarjian H, et al. Nilotinib monotherapy in patients with imatinib-resistant or -intolerant Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lym-phoblastic leukemia (ALL). Haematologica. 2007;92(suppl 1):556. Abstract.
108. Mueller MC, Erben P, Ernst T, et al. Molecular response according to type of preexisting BCR-ABL mutations after second line dasatinib therapy in chronic phase CML patients. Blood (ASH Annu Meet Abstracts). 2007;110:319. Abstract.
109. Guilhot F, Larson RA, O'Brien SG, et al. Time to complete cytoge-netic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy. Blood(ASH Annu Meet Abstracts). 2007;110:27.
110. Kantarjian HM, Quintas-Cardama A, O'Brien S, et al. Importance of early intervention with dasatinib at cytogenetic rather than hematologic resistance to imatinib. Blood (ASH Annu Meet Abstracts). 2007;110:1036. Abstract.
111. Cortes J, Giles F, O'Brien S, et al. Result of high-dose imatinib mesy-late in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood. 2003;102(1):83-86. Epub 2003 Mar 13.
112. Cortes JG, Baccarani M, Guilhot F, et al. First report of the TOPS study: a randomized phase III trial of 400 mg vs 800 mg imatinib in patients with newly diagnosed, previously untreated CML in chronic phase using molecular endpoints TOPS. Presented at the 13th Annual Congress of the European Hematology Association, June 13-15, 2008, Copenhagen, Denmark. 2008:402. Abstract.
113. Baccarani M, Haznedaroglu I, Porkka K, et al. A prospective randomized study of imatinib 400 mg vs 800 mg as a frontline therapy in Sokal high risk (HR) Ph-pos chronic myeloid leukemia (CML) patients. Presented at the 13th Annual Congress of the European Hematology Association, June 13-15, 2008, Copenhagen, Denmark. 2008:405. Abstract.
114. Andreas AP, Wolf DW, Fong DF, et al. High doses of imatinib mesy-late (800mg/day) significantly improve rates of major and complete cytoge-netic remissions (MCR, CCR). Results from the first planned interim analysis of a multicenter, randomised, 2-arm-phase III study comparing imatinib standard dose (400 mg/day) with imatinib high dose. Presented at the 13th Annual Congress of the European Hematology Association, June 13-15, 2008, Copenhagen, Denmark. 2008:406. Abstract.
115. Borthakur G, Kantarjian HM, O'Brien SM, et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). J Clin Oncol. 2008;26(May 20 suppl):7013. Abstract.
116. Cortes J, O'Brien S, Jones D, et al. Efficacy of nilotinib (formerly AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). Blood (ASH Annu Meet Abstracts). 2008;112:446.
117. Branford S, Seymour JF, Grigg A, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res. 2007;13(23):7080-7085.
118. Tam CS, Kantarjian H, Garcia-Manero G, et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood. 2008;112(3):516-518. Epub 2008 May 20.